Immune cells trained to fight ovarian cancer in new trial

NCT ID NCT06321484

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into the abdomen. The study aims to find the safest dose and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytokine-Induced Memory-like Natural Killer (CIML NK) cells
What this could lead to: If it works, this could point toward a new treatment option for recurrent ovarian cancer that is resistant to standard chemotherapy.
What could go wrong: This is a very early phase 1 trial with only 18 participants, so it may not show clear benefit or could have unexpected side effects. The treatment is experimental and not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma ovarian clear cell cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL OVARIAN CARCINOMA ENDOMETROID OVARIAN CARCINOMA OVARIAN CANCER OVARIAN CARCINOMA OVARIAN CARCINOMA, RECURRENT PLATINUM-RESISTANT OVARIAN CANCER RECURRENT OVARY CANCER

Contacts and locations

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.